Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 42

1.

Markers for efficacy of mammalian target of rapamycin inhibitor.

Liao YM, Sy A, Yen Y.

Anticancer Res. 2012 Oct;32(10):4235-44. Review.

PMID:
23060543
[PubMed - indexed for MEDLINE]
2.

mTOR kinase inhibitors as potential cancer therapeutic drugs.

Sun SY.

Cancer Lett. 2013 Oct 28;340(1):1-8. doi: 10.1016/j.canlet.2013.06.017. Epub 2013 Jun 20. Review.

PMID:
23792225
[PubMed - indexed for MEDLINE]
3.

mTOR inhibitors in cancer therapy.

Zaytseva YY, Valentino JD, Gulhati P, Evers BM.

Cancer Lett. 2012 Jun 1;319(1):1-7. doi: 10.1016/j.canlet.2012.01.005. Epub 2012 Jan 17. Review.

PMID:
22261336
[PubMed - indexed for MEDLINE]
4.

Emerging roles for mammalian target of rapamycin inhibitors in the treatment of solid tumors and hematological malignancies.

Khokhar NZ, Altman JK, Platanias LC.

Curr Opin Oncol. 2011 Nov;23(6):578-86. doi: 10.1097/CCO.0b013e32834b892d. Review.

PMID:
21892085
[PubMed - indexed for MEDLINE]
5.

Predictive biomarkers for the activity of mammalian target of rapamycin (mTOR) inhibitors.

Delbaldo C, Albert S, Dreyer C, Sablin MP, Serova M, Raymond E, Faivre S.

Target Oncol. 2011 Jun;6(2):119-24. doi: 10.1007/s11523-011-0177-6. Epub 2011 Apr 28. Review.

PMID:
21533544
[PubMed - indexed for MEDLINE]
6.

mTOR inhibitors: facing new challenges ahead.

Mavrommati I, Maffucci T.

Curr Med Chem. 2011;18(18):2743-62. Review.

PMID:
21649581
[PubMed - indexed for MEDLINE]
7.

Benefits of mTOR kinase targeting in oncology: pre-clinical evidence with AZD8055.

Marshall G, Howard Z, Dry J, Fenton S, Heathcote D, Gray N, Keen H, Logie A, Holt S, Smith P, Guichard SM.

Biochem Soc Trans. 2011 Apr;39(2):456-9. doi: 10.1042/BST0390456. Review.

PMID:
21428919
[PubMed - indexed for MEDLINE]
8.

mTOR signaling and drug development in cancer.

Dancey J.

Nat Rev Clin Oncol. 2010 Apr;7(4):209-19. doi: 10.1038/nrclinonc.2010.21. Epub 2010 Mar 16. Review.

PMID:
20234352
[PubMed - indexed for MEDLINE]
9.

Targeting the mTOR signaling network for cancer therapy.

Meric-Bernstam F, Gonzalez-Angulo AM.

J Clin Oncol. 2009 May 1;27(13):2278-87. doi: 10.1200/JCO.2008.20.0766. Epub 2009 Mar 30. Review.

PMID:
19332717
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

Clinical activity of mammalian target of rapamycin inhibitors in solid tumors.

Alvarado Y, Mita MM, Vemulapalli S, Mahalingam D, Mita AC.

Target Oncol. 2011 Jun;6(2):69-94. doi: 10.1007/s11523-011-0178-5. Epub 2011 May 4. Review.

PMID:
21541789
[PubMed - indexed for MEDLINE]
11.

Enhancing mTOR-targeted cancer therapy.

Wang X, Sun SY.

Expert Opin Ther Targets. 2009 Oct;13(10):1193-203. doi: 10.1517/14728220903225008. Review.

PMID:
19694499
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

ATP-competitive inhibitors of mTOR: an update.

Schenone S, Brullo C, Musumeci F, Radi M, Botta M.

Curr Med Chem. 2011;18(20):2995-3014. Review.

PMID:
21651476
[PubMed - indexed for MEDLINE]
13.

Mechanisms of mTOR inhibitor resistance in cancer therapy.

Carew JS, Kelly KR, Nawrocki ST.

Target Oncol. 2011 Mar;6(1):17-27. doi: 10.1007/s11523-011-0167-8. Epub 2011 Mar 9. Review.

PMID:
21547705
[PubMed - indexed for MEDLINE]
14.

mTOR signaling pathway and mTOR inhibitors in cancer therapy.

Gomez-Pinillos A, Ferrari AC.

Hematol Oncol Clin North Am. 2012 Jun;26(3):483-505, vii. doi: 10.1016/j.hoc.2012.02.014. Epub 2012 Mar 31. Review.

PMID:
22520976
[PubMed - indexed for MEDLINE]
15.

Targeting mTOR signaling pathway in ovarian cancer.

Mabuchi S, Hisamatsu T, Kimura T.

Curr Med Chem. 2011;18(19):2960-8. Review.

PMID:
21651485
[PubMed - indexed for MEDLINE]
16.

The mTOR pathway in lung cancer and implications for therapy and biomarker analysis.

Ekman S, Wynes MW, Hirsch FR.

J Thorac Oncol. 2012 Jun;7(6):947-53. doi: 10.1097/JTO.0b013e31825581bd. Review.

PMID:
22588151
[PubMed - indexed for MEDLINE]
17.

Biologic rationale and clinical activity of mTOR inhibitors in gynecological cancer.

Diaz-Padilla I, Duran I, Clarke BA, Oza AM.

Cancer Treat Rev. 2012 Oct;38(6):767-75. doi: 10.1016/j.ctrv.2012.02.001. Epub 2012 Feb 29. Review.

PMID:
22381585
[PubMed - indexed for MEDLINE]
18.

Mammalian target of rapamycin and head and neck squamous cell carcinoma.

Liao YM, Kim C, Yen Y.

Head Neck Oncol. 2011 Apr 24;3:22. doi: 10.1186/1758-3284-3-22. Review.

PMID:
21513566
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

mTOR kinase inhibitors as a treatment strategy in hematological malignancies.

Grzybowska-Izydorczyk O, Smolewski P.

Future Med Chem. 2012 Mar;4(4):487-504. doi: 10.4155/fmc.12.14. Review.

PMID:
22416776
[PubMed - indexed for MEDLINE]
20.

Mammalian target of rapamycin as a rational therapeutic target for breast cancer treatment.

LoRusso PM.

Oncology. 2013;84(1):43-56. doi: 10.1159/000343063. Epub 2012 Oct 30. Review.

PMID:
23128843
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk